Interleukin-6 initiates muscle- and adipose tissue wasting in a novel C57BL/6 model of cancer-associated cachexia.
Adipose tissue
C57BL/6
Cachexia
Cancer
Interleukin-6
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
23
08
2022
received:
20
01
2022
accepted:
26
09
2022
pubmed:
10
11
2022
medline:
4
2
2023
entrez:
9
11
2022
Statut:
ppublish
Résumé
Cancer-associated cachexia (CAC) is a wasting syndrome drastically reducing efficacy of chemotherapy and life expectancy of patients. CAC affects up to 80% of cancer patients, yet the mechanisms underlying the disease are not well understood and no approved disease-specific medication exists. As a multiorgan disorder, CAC can only be studied on an organismal level. To cover the diverse aetiologies of CAC, researchers rely on the availability of a multifaceted pool of cancer models with varying degrees of cachexia symptoms. So far, no tumour model syngeneic to C57BL/6 mice exists that allows direct comparison between cachexigenic- and non-cachexigenic tumours. MCA207 and CHX207 fibrosarcoma cells were intramuscularly implanted into male or female, 10-11-week-old C57BL/6J mice. Tumour tissues were subjected to magnetic resonance imaging, immunohistochemical-, and transcriptomic analysis. Mice were analysed for tumour growth, body weight and -composition, food- and water intake, locomotor activity, O CHX207, but not MCA207-tumour-bearing mice exhibited major clinical features of CAC, including systemic inflammation, increased plasma IL-6 concentrations (190 pg/mL, P ≤ 0.0001), increased energy expenditure (+28%, P ≤ 0.01), adipose tissue loss (-47%, P ≤ 0.0001), skeletal muscle wasting (-18%, P ≤ 0.001), and body weight reduction (-13%, P ≤ 0.01) 13 days after cancer cell inoculation. Adipose tissue loss resulted from reduced lipid uptake and -synthesis combined with increased lipolysis but was not associated with elevated beta-adrenergic signalling or adipose tissue browning. Muscle atrophy was evident by reduced myofibre cross sectional area (-21.8%, P ≤ 0.001), increased catabolic- and reduced anabolic signalling. Deletion of IL-6 from CHX207 cancer cells completely protected CHX207 In this study, we present CHX207 fibrosarcoma cells as a novel tool to investigate the mediators and metabolic consequences of CAC in C57BL/6 mice in comparison to non-cachectic MCA207-tumour-bearing mice. IL-6 represents an essential trigger for CAC development in CHX207-tumour-bearing mice.
Sections du résumé
BACKGROUND
Cancer-associated cachexia (CAC) is a wasting syndrome drastically reducing efficacy of chemotherapy and life expectancy of patients. CAC affects up to 80% of cancer patients, yet the mechanisms underlying the disease are not well understood and no approved disease-specific medication exists. As a multiorgan disorder, CAC can only be studied on an organismal level. To cover the diverse aetiologies of CAC, researchers rely on the availability of a multifaceted pool of cancer models with varying degrees of cachexia symptoms. So far, no tumour model syngeneic to C57BL/6 mice exists that allows direct comparison between cachexigenic- and non-cachexigenic tumours.
METHODS
MCA207 and CHX207 fibrosarcoma cells were intramuscularly implanted into male or female, 10-11-week-old C57BL/6J mice. Tumour tissues were subjected to magnetic resonance imaging, immunohistochemical-, and transcriptomic analysis. Mice were analysed for tumour growth, body weight and -composition, food- and water intake, locomotor activity, O
RESULTS
CHX207, but not MCA207-tumour-bearing mice exhibited major clinical features of CAC, including systemic inflammation, increased plasma IL-6 concentrations (190 pg/mL, P ≤ 0.0001), increased energy expenditure (+28%, P ≤ 0.01), adipose tissue loss (-47%, P ≤ 0.0001), skeletal muscle wasting (-18%, P ≤ 0.001), and body weight reduction (-13%, P ≤ 0.01) 13 days after cancer cell inoculation. Adipose tissue loss resulted from reduced lipid uptake and -synthesis combined with increased lipolysis but was not associated with elevated beta-adrenergic signalling or adipose tissue browning. Muscle atrophy was evident by reduced myofibre cross sectional area (-21.8%, P ≤ 0.001), increased catabolic- and reduced anabolic signalling. Deletion of IL-6 from CHX207 cancer cells completely protected CHX207
CONCLUSIONS
In this study, we present CHX207 fibrosarcoma cells as a novel tool to investigate the mediators and metabolic consequences of CAC in C57BL/6 mice in comparison to non-cachectic MCA207-tumour-bearing mice. IL-6 represents an essential trigger for CAC development in CHX207-tumour-bearing mice.
Identifiants
pubmed: 36351437
doi: 10.1002/jcsm.13109
pmc: PMC9891934
doi:
Substances chimiques
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-107Subventions
Organisme : Leducq Foundation
Organisme : Louis Jeantet Foundation
Organisme : DK Molecular Enzymology
ID : W901
Organisme : Austrian Science Fund
ID : F83
Organisme : Austrian Science Fund
ID : F7302
Organisme : Austrian Science Fund
ID : P30968
Organisme : Austrian Science Fund
ID : I5618
Organisme : DOC fellowship
ID : 25049
Organisme : aH2020-MSCA-ITN
ID : 859860
Organisme : BioTechMed-Flagship Project 'Midas'
Organisme : University of Graz
Organisme : Medical University of Vienna
Organisme : European Research Council
ID : 340896
Pays : International
Informations de copyright
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Nature. 2014 Sep 4;513(7516):100-4
pubmed: 25043053
Nat Med. 2016 Oct;22(10):1120-1130
pubmed: 27571348
J Neurosurg. 1987 Dec;67(6):852-7
pubmed: 3316531
PLoS One. 2014 Mar 25;9(3):e92966
pubmed: 24667661
J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):673-684
pubmed: 29978562
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1459-1475
pubmed: 33090732
Ann Palliat Med. 2019 Jan;8(1):13-23
pubmed: 30525767
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):
pubmed: 35210363
J Cachexia Sarcopenia Muscle. 2023 Feb;14(1):93-107
pubmed: 36351437
Trends Immunol. 2015 Feb;36(2):92-101
pubmed: 25616716
Int J Cancer. 1996 Nov 27;68(5):637-43
pubmed: 8938147
Am J Physiol Endocrinol Metab. 2012 Aug 1;303(3):E410-21
pubmed: 22669242
Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):2751-2760
pubmed: 31980524
Sci Rep. 2017 Aug 29;7(1):9640
pubmed: 28851899
Clin Transl Med. 2021 Jun;11(6):e417
pubmed: 34185433
Int J Mol Sci. 2020 Aug 31;21(17):
pubmed: 32878032
Oncotarget. 2017 Aug 10;8(61):104638-104653
pubmed: 29262667
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
Neurology. 2010 Feb 9;74(6):494-501
pubmed: 20142616
BMC Cancer. 2016 Feb 08;16:75
pubmed: 26856534
Expert Opin Biol Ther. 2011 Dec;11(12):1663-8
pubmed: 21995322
Mamm Genome. 2008 May;19(5):318-31
pubmed: 18392653
Eur J Haematol. 2014 Jul;93(1):9-18
pubmed: 24520908
Cancer Biol Ther. 2011 Jul 15;12(2):125-30
pubmed: 21532335
J Biol Chem. 2015 Apr 24;290(17):11177-87
pubmed: 25787076
Cell Metab. 2014 Sep 2;20(3):433-47
pubmed: 25043816
Lancet Oncol. 2013 May;14(6):e218-28
pubmed: 23639322
J Biol Chem. 2006 Dec 29;281(52):40236-41
pubmed: 17074755
J Cancer. 2020 Jun 28;11(17):5088-5098
pubmed: 32742456
Curr Opin Support Palliat Care. 2016 Dec;10(4):281-287
pubmed: 27454355
Nat Rev Dis Primers. 2018 Jan 18;4:17105
pubmed: 29345251
EMBO Rep. 2019 Apr;20(4):
pubmed: 30890538
J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1312-1332
pubmed: 34231343
Genes Dev. 2016 Mar 1;30(5):489-501
pubmed: 26944676
J Immunol. 1997 Apr 1;158(7):3359-65
pubmed: 9120294
Semin Cell Dev Biol. 2016 Jun;54:28-41
pubmed: 26860754
Science. 2011 Jul 8;333(6039):233-8
pubmed: 21680814
J Exp Med. 2021 Jun 7;218(6):
pubmed: 33851955
Am J Physiol Regul Integr Comp Physiol. 2008 Feb;294(2):R393-401
pubmed: 18056981